1Pagliaro LC, Keyhani A, Wilfiams D, et al. Repeated Intravesical Inxtilladons of an Adenoviral Vector in Pationts With Locally Advanced Bladder Cancer: A Phase I Study of p53Gene Therapy [J]. J Clin Oncol, 2003, 21 (12): 2247-2253.
2Frank DK. Gene Therapy for Head and Neck Cancer[J].Surg Oncol Clin N Am, 2002, 11(3): 589--606.
7Liangln Zhang, Dihua Yu, Mei Hu, et at. Wild-type P53 suppresses angiogenesis in human leiomyo-sarcoma andsynovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression[J]. Cancer Res, 2000, 60(13): 3655-3661.
8Buller RE, runnebanm IB, Karlan BY, et al. A phese Ⅰ /Ⅱ trial of rAd-P53 gene replacement in recurrent ovarian cancer[J].Cancer Gnen Ther, 2002, 9(7): 553-566.
9Swisher SG, Roth JA. Clinical update of Ad--p53 therapy for lung cancer[]]. Surg Oncol Clin N Am, 2002,11 (3): 521-535.
8[4]Cheng D, Rodriguez RM, Perkett EA, et al. Vascular endothelial growth factor in pleural fluid[J]. Chest, 1999,116(3): 760～765
9[5]Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions with malignant and nonmalignant disease[J]. Cancer, 1999, 85 (1): 178～187
10[9]Warmann SW, Fuchs J, Wilkens L, et al. Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan[J]. Med Pediatr Oncol, 2001, 37(5): 449～454
